Cosmo Pharmaceuticals N.V (C43) — Net Asset Quality Index
Cosmo Pharmaceuticals N.V (C43) has a Net Asset Quality Index of 79.8% as of December 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of €612.64 Million minus total liabilities of €123.46 Million yields net assets of €489.18 Million. A higher index indicates a stronger, lower-leverage balance sheet. Read Cosmo Pharmaceuticals N.V debt and liabilities for a breakdown of total debt and financial obligations.
Quality Index
Net Assets
Total Assets
Total Liabilities
Cosmo Pharmaceuticals N.V Net Asset Quality Index Over Time (2016–2025)
This chart shows how Cosmo Pharmaceuticals N.V's Net Asset Quality Index has evolved across 10 annual periods from 2016 to 2025. As of December 2025, the index stands at 79.8%, representing net assets of €489.18 Million against total assets of €612.64 Million EUR. For live market cap and overall valuation, see C43 market cap overview.
Annual Net Asset Quality Index for Cosmo Pharmaceuticals N.V (2016–2025)
The table below presents the year-by-year Net Asset Quality Index for Cosmo Pharmaceuticals N.V from 2016 to 2025, covering 10 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. Check Cosmo Pharmaceuticals N.V (C43) strategic asset index to assess the company's strategic physical and investment asset allocation.
| Year | Quality Index | Net Assets (EUR) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 79.8% | €489.18 Million | €612.64 Million | €123.46 Million | ▲ +1.8 pp |
| 2024 | 78.1% | €505.09 Million | €646.77 Million | €141.68 Million | ▲ +1.4 pp |
| 2023 | 76.7% | €403.62 Million | €526.04 Million | €122.42 Million | ▲ +15.7 pp |
| 2022 | 61.1% | €463.79 Million | €759.59 Million | €295.80 Million | ▼ -2.6 pp |
| 2021 | 63.6% | €512.68 Million | €805.56 Million | €292.88 Million | ▼ -3.5 pp |
| 2020 | 67.1% | €400.12 Million | €596.16 Million | €196.04 Million | ▼ -0.2 pp |
| 2019 | 67.3% | €393.73 Million | €585.16 Million | €191.43 Million | ▼ -3.8 pp |
| 2018 | 71.1% | €444.85 Million | €625.69 Million | €180.83 Million | ▼ -23.3 pp |
| 2017 | 94.4% | €470.12 Million | €497.97 Million | €27.86 Million | ▲ +0.7 pp |
| 2016 | 93.7% | €415.56 Million | €443.47 Million | €27.92 Million | — |